Itolizumab is a novel first-in-class humanized anti-CD6 monoclonal antibody, which Biocon developed and launched in India under the brand name ALZUMAb™ to treat moderate to severe plaque psoriasis in 2013.
TechnoConnect in Delhi saw a presence of 270+ healthcare fraternity representatives from 100+ healthcare institutions spread across the northern region of India and Nepal.
Digital diagnosis is now the default diagnosis of the lab for surgical pathology and 100 per cent of FFPE slides (formalin-fixed paraffin-embedded) are digitally scanned into high-resolution digital images.
Biocon Biologics, committed to enabling affordable access, launched its ‘Unlock Universal Access to Quality Insulins’ initiative in September 2019 with an announcement to provide recombinant human Insulin (rh-Insulin) at less than 10 US cents/day for Governments in Low and Middle-Income Countries (L
ICMR found antibiotic-resistant organisms in the digestive tracts of 2/3 healthy persons that it tested – why should that be sounding like an alarm bell?